Cellyan Biotechnology (HKPD) Common Equity (2024 - 2025)
Cellyan Biotechnology's (HKPD) quarterly Common Equity came in at $5.1 million in Q3 2025, down 3.9% year-on-year from $5.4 million in Q3 2024, and up 3.08% on a QoQ basis from $5.0 million in Q1 2025.
Cellyan Biotechnology (HKPD) Common Equity (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Common Equity data on file, last reported at $5.1 million in Q3 2025.
- On a quarterly basis, Common Equity fell 3.9% year-over-year to $5.1 million in Q3 2025; TTM through Sep 2025 was $5.1 million, a 3.9% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, up 17.31% from the prior year.
- Common Equity for Q3 2025 stood at $5.1 million, up from $5.0 million in the prior quarter.
- Over the last five years, Common Equity for HKPD reached as high as $5.4 million in Q3 2024 and fell as low as $4.3 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn | -2.17 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn | 3.40 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn | -2.83 Bn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn | 1.00 Mn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - | 180.93 Mn |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn | -99.01 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn | -464.77 Mn |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn | 10.10 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 | 1.85 Mn |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - | 5.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.14 Mn |
| Mar 31, 2025 | 4.99 Mn |
| Sep 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 4.25 Mn |